A three-lumen catheter for urethral drug administration
By designing the drug delivery channel and balloon structure of the three-lumen urinary catheter, the precision of intraurethral drug delivery and the long-term retention of the drug solution are achieved, solving the problem of inaccurate drug delivery in urethral stricture in existing technologies and improving the treatment effect.
Patent Information
- Application Number
- CN202411096551.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2044-08-12
AI Technical Summary
Existing technologies cannot achieve precise positioning of intraurethral drug delivery using urinary catheters, resulting in a fixed injection site and making it impossible to accurately deliver medication to areas of urethral stricture.
A three-lumen urinary catheter was designed, comprising a drug delivery channel, a drug delivery balloon, and a drug delivery tube. By using the drug delivery balloon and the sealing balloon in combination, precise drug delivery can be achieved to the location in the urethra where medication is needed. The injection and outflow of the drug solution are controlled by a constant pressure pump and a control valve.
This achieves precise intraurethral drug delivery and allows the drug solution to remain in the required location for an extended period, thus improving the treatment effect of urethral stricture.
Smart Images

Figure CN118949229B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of urinary catheter technology, specifically relating to a three-lumen urinary catheter that can be used for urethral drug administration. Background Technology
[0002] Urethral stricture is a common lower urinary tract disease in men. Its causes include perineal injury, iatrogenic injury, and chronic inflammation. The natural course of urethral stricture usually begins with damage and inflammation of the urethral mucosa, followed by abnormal proliferation of extracellular matrix at the site of injury and scar formation, which leads to a reduction in the urethral lumen and difficulty in urination.
[0003] In existing technologies, 5-fluorouracil (5-FU) combined with glucocorticoids can be used to treat urethral scars, but how to inject the drug into the urethra where treatment is needed is a problem that urgently needs to be solved.
[0004] For example, a urethral stricture drug delivery catheter with patent number CN202121157519.2 includes a catheter, a catheter fixing mechanism, a limiting mechanism at the anastomosis of the urethral stricture, a drug delivery mechanism, and a urethral stricture visual balloon dilator. Although this technical solution can inject drugs into the urethra through a catheter, the injection site is fixed, and the position of the catheter after insertion is also relatively fixed. Therefore, the injection site relative to the urethra is also relatively fixed. However, the sites for drug delivery within the length of the urethra are not fixed. Therefore, the prior art can only achieve drug delivery over a large area of the urethra and cannot achieve precise drug delivery to the site in the urethra that needs to be drug delivered through a catheter. Summary of the Invention
[0005] In view of this, the purpose of the present invention is to provide a three-lumen urinary catheter that can be used for urethral drug administration, so as to achieve precise drug administration to the site in the urethra where drug administration is required, thereby improving the treatment effect of urethral stricture.
[0006] To achieve the above objectives, the present invention provides the following technical solution:
[0007] This invention discloses a three-lumen urinary catheter for urethral drug administration, comprising a catheter body, an internal drug administration channel, and several evenly distributed drug administration balloons on the catheter body. Each drug administration balloon is annularly sleeved on the catheter body and communicates with the internal drug administration channel. Several evenly distributed permeation holes are provided on the side of the drug administration balloon facing the lateral end of the catheter body. A drug administration tube is provided within the drug administration channel, slidably connected to the channel. One end of the drug administration tube is located within the drug administration channel and is closed, while the other end extends out of the drug administration channel and is located outside the catheter body. A first drug administration port is provided on the end of the drug administration tube within the drug administration channel.
[0008] Furthermore, each of the drug delivery balloons is provided with a closed balloon 1-3 cm above the external end of the catheter body. The closed balloon is annularly sleeved on the catheter body and communicates with the inside of the drug delivery channel. The drug delivery tube is also provided with a second drug delivery hole matching the number of the first drug delivery holes. The distance between the first and second drug delivery holes matches the distance between the drug delivery balloon and the closed balloon. A spring is provided inside the closed end of the drug delivery tube. One end of the spring is fixed to the closed end of the drug delivery tube, and a sliding plug is provided on the other end of the spring. The sliding plug is located between the first and second drug delivery holes.
[0009] Furthermore, both the first and second administration holes are strip-shaped holes, and sealing rings are provided on the outer walls of the administration tubes at both the upper and lower ends of the first and second administration holes.
[0010] Furthermore, the drug delivery tube includes an upper tube and a lower tube. The upper tube has a drug delivery channel in the middle. The lower tube is hollow inside. The first drug delivery hole, the second drug delivery hole, the spring, and the sliding plug are all disposed inside the lower tube. The drug delivery channel is connected to the lower tube.
[0011] Furthermore, the inflation height of the drug delivery balloon and the sealing balloon is 0.3-1 mm.
[0012] Furthermore, the spring is a plastic spring.
[0013] Furthermore, the administration tube is a flexible tube.
[0014] Furthermore, a constant pressure pump is provided at one end of the administration tube located outside the main body of the urinary catheter, and a first control valve is provided on the administration tube.
[0015] Furthermore, the catheter body has a drainage channel in the middle, and at least one through drainage hole is provided at one end of the drainage channel inside the human body. A drainage pipe is provided at the other end of the drainage channel, and a second control valve is provided on the drainage pipe.
[0016] Furthermore, the catheter body, which is positioned opposite the drug delivery channel, is provided with an injection channel. The injection channel has a through injection hole at one end inside the human body. The catheter body is provided with an inflatable balloon that communicates with the injection hole. An injection tube is provided at the other end of the injection channel, and a third control valve is provided on the injection tube. The distance between the inflatable balloon and the end of the catheter body inside the human body is less than the distance between any drug delivery balloon and the end of the catheter inside the human body.
[0017] The beneficial effects of this invention are as follows:
[0018] (1) In this technical solution, the setting of the drug delivery tube, drug delivery balloon and drug delivery channel can accurately deliver drugs to the location in the patient's urethra where drugs need to be delivered, so that the catheter has the function of delivering drugs to the urethra.
[0019] (2) The design of the closed airbag, spring and sliding plug allows the drug solution injected into the urethra to stay at the site where the drug needs to be administered for a long time, so that the drug solution can have more sufficient contact with the site where the drug needs to be administered in the urethra, thus improving the effect of urethral drug administration.
[0020] Other advantages, objectives, and features of the invention will be set forth in the following description and will be apparent to those skilled in the art in some respects, or may be learned by practice of the invention. The objectives and other advantages of the invention can be realized and obtained through the following description. Attached Figure Description
[0021] To make the objectives, technical solutions, and beneficial effects of this invention clearer, the following figures are provided for illustration:
[0022] Figure 1 This is a three-dimensional schematic diagram of the three-lumen urinary catheter of the present invention;
[0023] Figure 2 This is a three-dimensional schematic diagram of the three-lumen catheter of the present invention from another perspective;
[0024] Figure 3 This is a schematic diagram of the front view and cross-sectional view of the three-lumen urinary catheter of the present invention;
[0025] Figure 4 This is a schematic diagram showing the internal channel arrangement of the main body of the three-lumen urinary catheter of the present invention;
[0026] Figure 5 This is a schematic cross-sectional view of the infusion tube in the three-lumen urinary catheter of the present invention;
[0027] Figure 6 For the present invention Figure 3 A magnified view of a portion of point A in the middle;
[0028] Figure 7 For the present invention Figure 4 A magnified view of a portion of point B in the middle;
[0029] Figure 8 For the present invention Figure 5 A magnified view of a portion of point C.
[0030] The following labels are shown in the attached diagram:
[0031] The catheter consists of: 1. Main body of the catheter; 2. Injection channel; 3. Inflation balloon; 4. Injection tube; 5. Third control valve; 6. Drainage channel; 7. Drainage hole; 8. Drainage tube; 9. Second control valve; 10. Drug delivery channel; 11. Drug delivery balloon; 12. Sealing balloon; 13. Permeation hole; 14. Drug delivery tube; 15. First control valve; 16. Lower tube; 17. Second drug delivery hole; 18. First drug delivery hole; 19. Spring; 20. Sliding plug; 21. Upper tube; 22. Drug delivery flow channel. Detailed Implementation
[0032] like Figures 1-8 As shown, the present invention discloses a three-lumen urinary catheter for urethral administration, comprising a catheter body 1, an internal administration channel 10, and several evenly distributed administration balloons 11 on the catheter body 1. The administration balloons 11 are annularly sleeved on the catheter body 1 and communicate with the internal administration channel 10 via through holes. Several evenly distributed permeation holes 13 are provided on the side of the administration balloons 11 facing the outer side of the catheter body 1. An administration tube 14 is provided inside the administration channel 10 and is slidably connected within the administration channel 10. One end of the administration tube 14 is located inside the administration channel 10 and is closed, while the other end of the administration tube 14 extends out of the administration channel 10 and is located outside the catheter body 1. A first administration hole 18 is provided on the end of the administration tube 14 located inside the administration channel 10.
[0033] The working principle of the above technical solution for achieving precise drug delivery to the site inside the urethra is as follows:
[0034] When medication administration is required, the medication site in the urethra must first be determined. Then, by matching the length of the catheter body 1, the position of the medication balloon 11 at the urethral medication site is determined. Next, the first medication port 18 on the medication tube 14 is pulled to match the position of the medication balloon 11. The catheter is then inserted into the patient. When medication needs to be administered to the urethra, the medication is continuously injected from outside the medication tube 14. After entering the medication tube 14, the medication flows out from the first medication port 18, then through the through-hole connecting the medication channel 10 and the medication balloon 11 into the medication balloon 11. The medication balloon 11 then inflates, and finally, the medication flows out from the permeation hole 13 of the medication balloon. The outflow location is the location in the patient's urethra where medication needs to be administered. The reason for the permeation hole 13 facing outwards is that after the catheter is inserted, the catheter is in a relaxed, drooping state, meaning the permeated medication flows downwards towards the drooping part of the urethra, thus covering the area where medication needs to be administered and achieving the medication administration operation.
[0035] It is easy to understand that, due to the pressure from the patient's urethra, the outer wall of the administration tube 14 and the inner wall of the administration channel 10 can achieve a certain degree of sealing. Therefore, most of the medication will be depressurized by entering the administration balloon 11. Even if a small amount of medication enters the space between the inner wall of the administration channel 10 and the outer wall of the administration tube 14, it will not significantly affect the effectiveness of this technical solution. Of course, a clip can be installed on the part of the administration tube 14 and the administration channel 10 located on the outside of the body to further seal the contact gap between them. Meanwhile, the material of the catheter body 1 is existing technology and will not be described in detail here.
[0036] In one feasible embodiment, a sealing balloon 12 is provided 1-3 cm above the external end of the catheter body 1, preferably 2 cm above the administration balloon 11. The sealing balloon 12 is annularly sleeved on the catheter body 1 and communicates with the inside of the administration channel 10. The administration tube 14 is also provided with a second administration hole 17 matching the number of the first administration holes 18. The distance between the first administration holes 18 and the second administration holes 17 matches the distance between the administration balloon 11 and the sealing balloon 12. A spring 19 is provided inside the closed end of the administration tube 14. One end of the spring 19 is fixed to the closed end of the administration tube 14, and a sliding plug 20 is provided on the other end of the spring 19. The sliding plug 20 can be understood as a rubber piston and is located between the first administration hole 18 and the second administration hole 17.
[0037] The working principle of the above technical solution is as follows:
[0038] First, determine the required length and location of the urethra for drug administration. Then, determine the pre-made matching drug administration balloon 11 and sealing balloon 12 when the main body of the catheter is located inside the urethra. The matching method is that the drug administration site is located between the drug administration balloon 11 and the sealing balloon 12. Then, pull the drug administration tube 14 to the matching position and insert the catheter. When drug administration is needed, simply push the drug solution from the end of the drug administration tube 14. After the drug solution enters the inside of the drug administration tube 14, due to the obstruction of the sliding plug 20, the drug solution can only enter the inside of the sealing balloon 12 through the second drug administration port 17, causing the sealing balloon 12 to inflate. That is, the expansion of the sealing balloon 12 will contact the inner wall of the urethra. The spring 19 touches the surface of the drug delivery site and then seals the downward-facing end. When the injection pressure increases, the drug overcomes the resistance of the spring 19 and pushes the sliding plug 20 to move. When the sliding plug 20 moves below the first drug delivery hole 18, the drug can enter the drug delivery airbag 11 from the first drug delivery hole 18 and then be discharged from the permeation hole 13 to perform the drug delivery operation. During the drug delivery process, as long as a constant pressure is maintained, continuous permeation drug delivery can be achieved. Of course, the pressure is related to the friction of the spring 19 and the sliding plug 20. As for the determination of the specific pressure, it can be obtained from a limited number of experiments during the design process, which will not be elaborated on here.
[0039] The advantage of this setup is that the sealed airbag 12, to a certain extent, seals off both ends of the urethra at the site where medication needs to be administered, allowing the medication to remain in that area for a longer period of time. In other words, the medication can soak that area. Compared to the medication flowing through the site where medication needs to be administered, this setup can further improve the accuracy and effectiveness of medication administration.
[0040] It is easy to understand that multiple models of catheters can be set according to the length of the urethra and the length that may be needed for drug administration, such as the distance between the drug administration balloon 11 and the sealing balloon 12 being 1cm, 2cm, 5cm and 7cm, etc.
[0041] In one feasible embodiment, both the first administration port 18 and the second administration port 17 are strip-shaped holes, and sealing rings are provided on the outer walls of the administration tubes 14 at both ends of the first administration port 18 and the second administration port 17. The purpose of the strip-shaped first administration port 18 and the second administration port 17 is to increase the communication range with the through holes on the administration airbag 11 and the sealing airbag 12, because the position of the administration tube 14 in the administration channel 10 may rotate. If it rotates, there may be a problem of not being able to communicate. Of course, the rotation of the administration tube 14 in the administration channel 10 can also be restricted by setting ridges and grooves, but this will increase the complexity of this technical solution. The setting of the sealing rings can effectively seal the gap between the administration tubes 14 at both ends of the first administration port 18 and the second administration port 17 and the administration channel 10, further preventing the liquid medicine from flowing into the gap and causing pressure leakage.
[0042] In one feasible embodiment, the drug delivery tube 14 includes an upper tube 21 and a lower tube 16. The wall thickness of the upper tube 21 is greater than that of the lower tube 16. This can be understood as the upper tube 21 having a drug delivery channel 22 in its middle. The diameter of the drug delivery channel 22 is smaller than the diameter of the drug delivery tube 14, specifically one-fifth of the diameter of the drug delivery tube 14, which can be determined according to the actual situation. The lower tube 16 is hollow inside, mainly to provide an installation position. That is, the first drug delivery hole 18, the second drug delivery hole 17, the spring 19, and the sliding plug 20 are all located inside the lower tube 16, and the drug delivery channel 22 is connected to the lower tube 16.
[0043] The advantage of this design is that most of the length of the drug delivery tube 14 is not covered at the top. Therefore, when administering the drug, the volume of the drug solution occupied by the top tube is the same as the volume of the drug delivery channel 22. Thus, only a small amount of drug solution is needed to fill it and then pressurize it for delivery. This design reduces the volume of drug solution used and saves drug solution.
[0044] In one feasible method, the inflation height of the administration balloon 11 and the sealing balloon 12 is 0.3-1mm. The inflation height refers to the distance between the catheter body 1 and the urethra at that location after inflation. The distance should be relatively small while achieving compression and sealing to avoid excessive compression of the urethra and causing discomfort to the patient. Preferably, it is 0.5mm, but it can be set according to the situation.
[0045] In one feasible embodiment, the spring 19 is a plastic spring 19, which will not be corroded or rusted by the liquid.
[0046] In one feasible embodiment, the administration tube 14 is a flexible tube, specifically referring to the endoscopic tube in the prior art. Of course, the diameter of the administration tube 14 can be determined according to the actual situation.
[0047] In one feasible embodiment, a constant pressure pump is provided at one end of the administration tube 14 located outside the main body 1 of the urinary catheter, and a first control valve 15 is provided on the administration tube 14. The function of the constant pressure pump is to inject the drug solution into the administration tube 14 at a constant pressure, thereby improving the drug injection effect.
[0048] In one feasible embodiment, the catheter body 1 has a drainage channel 6 in the middle. The drainage channel 6 has at least one through drainage hole 7 at one end inside the body. The other end of the drainage channel 6 has a drainage tube 8 with a second control valve 9. The function of the drainage channel 6 is to drain the medication in the patient's bladder to the outside through the drainage hole 7. The specific working principle will not be elaborated here.
[0049] In one feasible embodiment, the catheter body 1, which is positioned opposite the drug delivery channel 10, is provided with an injection channel 2. The injection channel 2 has a through injection hole at one end inside the body. The catheter body 1 is provided with an inflatable balloon 3, which is connected to the injection hole. The other end of the injection channel 2 is provided with an injection tube 4, which is provided with a third control valve 5. The distance between the inflatable balloon 3 and the end of the catheter body 1 inside the body is less than the distance between any drug delivery balloon 11 and the end of the catheter inside the body. By injecting liquid into the injection channel 2 through the injection tube 4, the inflatable balloon 3 can be inflated and locked inside the patient's bladder, preventing the catheter from dislodging. The specific working principle and structure will not be described in detail here.
[0050] It should be noted that in this technical solution, the way the drug delivery balloon 11 and the sealing balloon 12 are set on the catheter body 1 is the same as the way the inflatable balloon 3 on the catheter in the prior art is set. When no pressure is applied, the two are in close contact with the outer surface of the catheter body 1, and they will only inflate when pressure is applied.
[0051] Finally, it should be noted that the above preferred embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit it. Although the present invention has been described in detail through the above preferred embodiments, those skilled in the art should understand that various changes can be made to it in form and detail without departing from the scope defined by the claims of the present invention.
Claims
1. A three-lumen urinary catheter for urethral administration, characterized in that: The catheter includes a main body, an internal drug delivery channel, and several evenly distributed drug delivery balloons. Each drug delivery balloon is annularly sleeved on the main body and communicates with the internal drug delivery channel. Several evenly distributed permeation holes are located on the side of the main body facing outwards. A drug delivery tube is located within the drug delivery channel and is slidably connected thereto. One end of the drug delivery tube is located within the drug delivery channel and is closed. The other end of the drug delivery tube extends out of the drug delivery channel and is located outside the main body. A first... Drug administration ports; each of the drug administration balloons is positioned 1-3 cm above the external end of the catheter body and is fitted with a closed balloon. The closed balloon is annularly sleeved on the catheter body and communicates with the interior of the drug administration channel. The drug administration tube also has a second drug administration port matching the number of the first drug administration ports. The distance between the first and second drug administration ports matches the distance between the drug administration balloon and the closed balloon. A spring is provided inside the closed end of the drug administration tube. One end of the spring is fixed to the closed end of the drug administration tube, and a sliding plug is provided on the other end of the spring. The sliding plug is located between the first and second drug administration ports.
2. A three-lumen urinary catheter for urethral drug administration according to claim 1, characterized in that: Both the first and second administration holes are strip-shaped holes, and sealing rings are provided on the outer walls of the administration tubes at both ends of the first and second administration holes.
3. A three-lumen urinary catheter for urethral drug administration according to claim 1, characterized in that: The drug delivery tube includes an upper tube and a lower tube. The upper tube has a drug delivery channel in the middle. The lower tube is hollow inside. The first drug delivery hole, the second drug delivery hole, the spring, and the sliding plug are all disposed inside the lower tube. The drug delivery channel is connected to the lower tube.
4. A three-lumen urinary catheter for urethral drug administration according to claim 1, characterized in that: The inflation height of the drug delivery airbag and the sealing airbag is 0.3-1 mm.
5. A three-lumen urinary catheter for urethral administration according to claim 1, characterized in that: The spring is a plastic spring.
6. A three-lumen urinary catheter for urethral administration according to claim 1, characterized in that: The administration tube is a flexible tube.
7. A three-lumen urinary catheter for urethral administration according to claim 1, characterized in that: The drug delivery tube is equipped with a constant pressure pump at one end located outside the main body of the urinary catheter, and a first control valve is provided on the drug delivery tube.
8. A three-lumen urinary catheter for urethral administration according to claim 1, characterized in that: The catheter body has a drainage channel in the middle, and at least one through drainage hole is provided at one end of the drainage channel inside the human body. A drainage pipe is provided at the other end of the drainage channel, and a second control valve is provided on the drainage pipe.
9. A three-lumen urinary catheter for urethral administration according to claim 1, characterized in that: The catheter body, which is positioned opposite to the drug delivery channel, has an injection channel. The injection channel has a through injection hole at one end inside the body. The catheter body has an inflatable balloon that communicates with the injection hole. The other end of the injection channel has an injection tube with a third control valve. The distance between the inflatable balloon and the end of the catheter body inside the body is less than the distance between any drug delivery balloon and the end of the catheter inside the body.
Citation Information
Patent Citations
Urethral stenosis administration ureter
CN215961697U
Anorectal administration device
CN111658984A
Rectum and colon administration device
CN115300765A
